Kalaris Therapeutics (KLRS) Treasury Shares (2019 - 2025)
Kalaris Therapeutics (KLRS) posted quarterly Treasury Shares of $141.0 for Q4 2025, down 100.0% year-over-year from $43.2 million in Q4 2024, and down 75.09% quarter-over-quarter from $566.0 in Q3 2025.
Kalaris Therapeutics (KLRS) Treasury Shares (2019 - 2025) Analysis & Trends
Kalaris Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $141.0 for Q4 2025.
- In Q4 2025, Treasury Shares fell 100.0% year-over-year to $141.0; the TTM figure through Dec 2025 stood at $141.0 (down 100.0% YoY), while the FY2025 annual figure was $141.0, down 100.0% from the prior year.
- Treasury Shares for Q4 2025 stood at $141.0, down from $566.0 in the prior quarter.
- The five-year high for Treasury Shares was $43.2 million in Q1 2024, with the low at $141.0 in Q4 2025.
- The 5-year median for Treasury Shares is $3.3 million (2021), against an average of $12.4 million.
- The sharpest annual moves came in 2023 and 2025: Treasury Shares soared 1770.0% in 2023, then plunged 100.0% in 2025.
- Kalaris Therapeutics' Treasury Shares stood at $2.9 million in 2021, then decreased by 21.9% to $2.2 million in 2022, then jumped by 1770.0% to $41.9 million in 2023, then gained by 3.06% to $43.2 million in 2024, then slumped by 100.0% to $141.0 in 2025.
- Business Quant data shows KLRS's Treasury Shares at $141.0 in Q4 2025, $566.0 in Q3 2025, and $991.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 141.00 |
| Dec 31, 2025 | 141.00 |
| Sep 30, 2025 | 566.00 |
| Sep 30, 2025 | 566.00 |
| Jun 30, 2025 | 991.00 |
| Jun 30, 2025 | 991.00 |
| Mar 31, 2025 | 1,415.00 |
| Mar 31, 2025 | 1,415.00 |
| Dec 31, 2024 | 43.15 Mn |
| Dec 31, 2024 | 43.15 Mn |
| Sep 30, 2024 | 43.15 Mn |
| Sep 30, 2024 | 43.15 Mn |
| Jun 30, 2024 | 43.15 Mn |
| Jun 30, 2024 | 43.15 Mn |
| Mar 31, 2024 | 43.15 Mn |
| Mar 31, 2024 | 43.15 Mn |
| Dec 31, 2023 | 41.87 Mn |
| Dec 31, 2023 | 41.87 Mn |
| Sep 30, 2023 | 3.41 Mn |
| Sep 30, 2023 | 3.41 Mn |